[Indications and results of interstitial hypophyseal stereo-gammatherapy in the treatment of diabetic retinopathy].
New interest for pituitary neurosurgery in diabetic retinopathy is based on several data: long-term efficacy of various medical therapeutic agents is still unproved, ocular treatment by photocoagulation remains symptomatic, growth-hormone (HGH) has a permissive or supportive role in the development of diabetic retinopathy. Stereo-GIHF performs the pituitary interstitial irradiation by stereotaxic implantation of a gamma point emitter (198Au) and results in the selective blockade of HGH secretion peaks. Different from all other procedures achieving a more or less complete hypophysectomy, Stereo-GIHF introduces a new trend for the functional neurosurgical treatment of diabetic retinopathy.
D000302:Adrenal Cortex / Q000528:radiation effects; D000328:Adult; D003930:Diabetic Retinopathy / Q000532:radiotherapy*; D005260:Female; D006050:Gold Radioisotopes / Q000627:therapeutic use; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010053:Ovary / Q000528:radiation effects; D010910:Pituitary Irradiation / Q000009:adverse effects / Q000379:methods*; D013238:Stereotaxic Techniques; D013737:Testis / Q000528:radiation effects; D013961:Thyroid Gland / Q000528:radiation effects
D006050:Gold Radioisotopes; D013006:Growth Hormone
Indications et résultats de la stéréo-gammathérapie interstitielle hypophysaire freinatrice (stéréo-GIHF) dans le traitement de la rétinopathie diabétique.